The HealthyWomen Dinner: The Difference Between Men and Women in Clinical Research

Table at HealthWomen DinnerHealth Decisions was pleased to participate in the 2018 HealthyWomen dinner, held at the Italian Embassy in Washington June 13, where the theme was “‘Alla Nostra Salute! To Our Health’ – Celebrating innovation that advances women’s health research and advocacy for future generations.” HealthyWomen is an independent nonprofit organization addressing one of many underserved needs in women’s health – the need for accurate information about women’s health issues and treatment resources.

The keynote speaker at the dinner was John Whyte, MD, MPH, Director of Professional Affairs and Stakeholder Engagement at the Center for Drug Evaluation and Research at FDA. His speech was devoted to advancing diversity in clinical trials and some of the latest strides towards greater parity between male/female participation as well as race/ethnicities represented. Dr. Whyte emphasized the importance of prioritizing the inclusion of women in clinical research, stating, “We don’t know the difference between men and women in clinical research unless we choose to explore it.”

Health Decisions Team at HealthWomen Dinner in Washington, DCHealth Decisions’ CEO Patrick Phillips, BSc. (Hons), D.Phil., led the Health Decisions team at the dinner. Dr. Phillips was joined at the event by Rachel Hardin, Head of Business Development, and Kristin Snipes, Associate Director, Clinical Operations.

“This event provides further evidence of the momentum building for increased participation of women in clinical research,” Dr. Phillips said. “NIH, FDA and advocacy groups agree on the importance of collecting data on female response to investigational drugs because it can differ from male response and physicians need information to guide treatment decisions for female patients. In the absence of valid female-specific information about new drugs, women will remain at greater risk of adverse events. There is some support in the biopharma industry for increased female participation in clinical research. We hope to see this grow. We look forward to discussing female participation in research at DIA in Boston both as an industry concern and as a feature of individual development programs.”

During DIA 2018, Health Decisions’ Chief Medical Officer Andrea S. Lukes, MD, MHSc, FACOG, and Clint Dart, Senior Director, Biostatistics and Programming, will participate in Session #108, From Patients and Advocacy Groups to Operations and Beyond: Obtaining and Incorporating Input from Stakeholders in Protocol Design Monday, June 25, 11:00am – 12:00pm. Also presenting at the session will be Michelle Witkop, DNP, Head of Research, National Hemophilia Foundation. A key topic of the session will be the importance of incorporating input from advocacy groups in study planning and protocol development.

To schedule a meeting with a Health Decisions clinical development expert at DIA 2018 in Boston June 24-28, please contact us.

 

2018-06-19T21:20:45+00:00
SUBMIT RFP